[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates significant performance growth in H1 2025, with revenue projected to increase by 18-24% and net profit attributable to shareholders by 35-62% H1 2025 Performance Forecast vs. Prior Year Comparison | Indicator | H1 2025 Forecast (CNY Millions) | H1 2024 Officially Disclosed (CNY Millions) | Year-over-Year Growth Rate | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 400 - 420 | 339.77 | 18% - 24% | | **Net Profit Attributable to Parent** | 61 - 73 | 45.05 | 35% - 62% | | **Net Profit Attributable to Parent (Excluding Non-Recurring Items)** | 55 - 65 | 36.54 | 51% - 78% | - These performance forecast figures are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[2](index=2&type=chunk) [Prior Year Performance Review](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E4%B8%9A%E7%BB%A9%E6%83%85%E5%86%B5) This section presents H1 2024 performance as a comparative baseline, including operating revenue of approximately CNY 340 million and net profit attributable to parent of CNY 45.05 million H1 2024 Performance Overview | Indicator | Amount (CNY Millions) | | :--- | :--- | | **Operating Revenue** | 339.77 | | **Net Profit Attributable to Parent Company Shareholders** | 45.05 | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items)** | 36.54 | [Key Drivers of Current Period Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8C%96%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) Performance growth is primarily driven by the company's focus on core business, enhanced marketing, and product innovation, leading to approximately 20% sales growth in key products - The company focused on its core separation, purification, and analytical testing businesses, continuously strengthening marketing, application technology development, and product iteration and innovation[4](index=4&type=chunk)[5](index=5&type=chunk) - Core businesses, including chromatographic packing and media products, achieved approximately **20% sales revenue growth** in the first half, significantly contributing to performance improvement[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company confirms no significant uncertainties have been identified that could impact the accuracy of this performance forecast - The company has not identified any significant uncertainties affecting the accuracy of this performance forecast[6](index=6&type=chunk) [Other Explanatory Matters](index=2&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) Investors are reminded that the disclosed data are preliminary, and final financial figures will be based on the official H1 2025 report, with investment risks noted - The forecast data provided are preliminary, and specific financial figures will be subject to the company's officially disclosed H1 2025 report[7](index=7&type=chunk)

Summary of Conference Call on Life Sciences Services in the Pharmaceutical Sector Industry Overview - The life sciences services sector is fundamental to the biological sciences field, with a current domestic substitution rate of less than 30%, and 0% in high-end scientific instruments compared to international giants like Thermo Fisher and Danaher [1][3] - Domestic companies are significantly smaller in scale compared to their international counterparts, with Thermo Fisher projected to generate $43 billion in revenue in 2024 and Danaher close to $24 billion, while few domestic companies exceed $500 million in annual revenue [3] Core Points and Arguments - Achieving domestic substitution requires a multi-faceted approach, including enhancing basic scientific education to improve high-end talent cultivation and incorporating high-end scientific instrument R&D into national planning through government support [1][4] - Domestic enterprises need to form positive feedback loops with upstream and downstream supply chains, accelerating product upgrades through feedback from lower-end markets to break into high-end markets [1][5] - The uncertain international trade environment is prompting multinational companies to accelerate local supply chain layouts, which in turn supports the development of domestic industries [1][5] Production Material Substitution - Progress has been made in certain segments of production materials, but the substitution process must be gradual due to the necessity of these materials in the commercialization of innovative drugs, which have long cultivation cycles [1][6] - The COVID-19 pandemic has accelerated the substitution of imported raw materials in industrial production, leading many pharmaceutical companies to prefer domestic materials during early research stages and to make changes during Phase III clinical trials and commercialization to ensure supply chain security and cost control [1][6] Notable Companies and Opportunities - In the scientific instrument sector, attention should be given to Focused Technology, whose subsidiary, Puyutech, has made significant breakthroughs in the mass spectrometry field [2][7] - In the production materials sector, Aopumai in the culture medium segment has rapidly increased its pipeline project numbers, while Nanwei Technology and Saifen Technology in the filler segment are also recommended for their strong quality [2][7]

Group 1: Education Reform and New University Models - The current education system needs to shift from a "screening" model to an "activation" model, focusing on unlocking potential rather than solely relying on standardized test scores [1] - New types of research universities are emerging, characterized by innovative governance, talent cultivation, and research organization, with a focus on collaboration with industry [2] - The concept of "activation-type universities" is proposed, which would not use a single score as the admission criterion but instead employ a flexible, comprehensive selection mechanism [1][2] Group 2: Industry Collaboration and Talent Development - There is a disconnect between higher education talent cultivation and industry needs, highlighting the necessity for integrating market-oriented and product-oriented thinking into graduate education [3] - Collaborative programs, such as the Huawei Experimental Class at Nanjing University and the Tencent AI Class at Shenzhen University, exemplify the trend of universities partnering with companies to create specialized training programs [4] - The integration of research and education is emphasized as a way to ensure educational quality remains at the forefront [4] Group 3: Regional Education Disparities - The distribution of higher education resources is uneven, with a need for more institutions in underdeveloped regions, particularly in central and western China [5] - Despite having the highest number of universities, Henan Province faces challenges such as a lack of high-quality institutions and a high number of students competing for limited spots [11][14] - The establishment of new universities and the cultivation of a "second tier" of institutions in Henan aims to address these disparities and enhance local talent supply [14]

Core Viewpoint - Suzhou Nanwei Technology Co., Ltd. has announced the adjustment of the implementation subject for granting employee stock ownership platform shares to incentivize high-end talent and core employees [1][2][3] Group 1: Granting Employee Stock Ownership - The company plans to grant a total of 1,817,848.42 yuan worth of shares, corresponding to 3,289,440 shares, to 26 incentive targets [1] - The original holding platform subjects, Suzhou Nayan and Suzhou Nazhuo, faced limitations due to the number of partners, leading to the establishment of a new partnership, Suzhou Industrial Park Nayu Management Consulting Partnership [2] Group 2: Impact of Adjustments - The adjustment of the implementation subject for granting employee stock ownership will not have a substantial impact on the company's financial status and operating results [2] - The adjustment complies with relevant laws and regulations and does not harm the interests of the company and its shareholders [2][3] Group 3: Review Procedures and Opinions - The adjustment was approved during the third board meeting held on June 30, 2025 [2] - The Compensation and Assessment Committee confirmed that the adjustment aligns with the Shanghai Stock Exchange's regulations and the revised employee stock ownership plan [2] - The Supervisory Board also agreed that the adjustment followed the necessary review and disclosure procedures, ensuring no harm to shareholder interests [3]

根据公司2022年第三次临时股东大会批准修订的《员工股权激励计划》，为 引进高端人才和专家资源、激励部分核心员工，2022年9月22日召开的第二届董 事会第十五次会议，审议通过《关于向激励对象授予员工持股平台财产份额的议 案》，决定向牟一萍、赵顺、金百胜等26名激励对象授予员工持股平台合计 2,376,006.31元的财产份额（对应公司股份4,299,440股,占公司总股本的 1.07%），其中苏州纳研管理咨询合伙企业（有限合伙）（以下简称"苏州纳 研"）的授予份额为1,817,848.42元（对应公司股份3,289,440股）；苏州纳卓 管理咨询合伙企业（有限合伙）（以下简称"苏州纳卓"）的授予份额为 558,157.89元（对应公司股份1,010,000股）。该财产份额授予后通过持股平台 苏州纳卓和苏州纳研的执行事务合伙人苏州纳百管理咨询有限公司（以下简称 "苏州纳百"）向激励对象转让方式完成。 二、向激励对象授予员工持股平台财产份额的进展情况 因原定授予财产份额的持股平台主体苏州纳研和苏州纳卓的合伙人人数限 制，为顺利推进上述向激励对象授予员工持股平台财产份额事项，公司决定由苏 州纳百与被授予的26名激 ...

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为苏州纳 微科技股份有限公司（以下简称"纳微科技"或"公司"）首次公开发行股票并 在科创板上市的持续督导保荐人，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公司首 次公开发行股票部分募投项目结项并将节余募集资金永久补充流动资金及部分 募投项目延期事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 4 月 21 日出具的《关于同意苏州纳微科技股份有限公司首次公开发行股票注册的批 复》（证监许可〔2021〕1395 号），公司首次向社会公开发行人民币普通股（A） 股 4,400 万股，每股发行价格为 8.07 元，募集资金总额为人民币 35,508.00 万元； 扣除发行费用后实际募集资金净额为人民币 30,793.61 万元。上述募集资金已于 2021 年 6 月 18 日全部到账并经容诚会计师事务所（特殊普通合伙）对公司首次 公开发行股票的 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-022 苏州纳微科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金及部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于2025年6月30日召开第三 届董事会第七次会议和第三届监事会第五次会议，审议通过《关于部分募投项目 结项并将节余募集资金永久补充流动资金及部分募投项目延期的议案》，同意公 司首次公开发行股票募集资金投资项目"研发中心及应用技术开发建设项目子项 目——新型磁分离介质研发项目"结项并将节余募集资金用于永久补充流动资金， 同意将募投项目"海外研发和营销中心建设项目"达到预定可使用状态的时间延 期至2026年6月。本次部分募投项目延期仅涉及项目进度的变化，未改变募投项目 的投资内容、投资总额、实施主体，不会对募投项目的实施造成实质性影响。 本次事项已经公司第三届董事会战略委员会审议通过，公司监事会发表了明 确同意的意见，保荐机构中信证券股份有限公司对本事项出具了 ...

1、国常会：以"十年磨一剑"的坚定决心，加快推进高水平科技自立自强 重要程度：★★★★★ 国务院总理李强6月27日主持召开国务院常务会议，听取关于贯彻落实全国科技大会精神加快建设科技强 国情况的汇报，部署健全"高效办成一件事"重点事项常态化推进机制，审议通过《农村公路条例(草 案)》。 2、央行：建议加大货币政策调控强度，提高货币政策调控前瞻性、有效性 重要程度：★★★★ 根据央行网站消息，中国人民银行货币政策委员会2025年第二季度(总第109次)例会于6月23日召开。 会议研究了下阶段货币政策主要思路，建议加大货币政策调控强度，提高货币政策调控前瞻性、针对性、 有效性，根据国内外经济金融形势和金融市场运行情况，灵活把握政策实施的力度和节奏。 主板风险警示股票价格涨跌幅限制调整后，有望提升定价效率，缓解其过度波动现象，并减少连续涨停或 跌停的发生。市场影响预计中性，该调整不会改变整体价格走势。同时需注意的是，调整后这类股票的日 内波动空间将增大。 4、商务部：中国将加快向美国出口稀土 美方相应取消对华有关限制措施 重要程度：★★★ 商务部新闻发言人就中美伦敦框架有关情况答记者问。有记者提问：近日，美方有关官 ...

Core Viewpoint - The article discusses the upcoming 2025 AntibodyPlus Innovation Summit, highlighting the evolution of antibody drug development and the integration of various technologies in the biotech industry, particularly in China [5]. Background - The FDA approved the first monoclonal antibody in 1986, marking nearly 40 years of advancements in antibody therapies. The concept of AntibodyPlus was introduced by the Chinese Antibody Association in July 2021 to reflect new trends in antibody drug development, including combinations with cells, nucleic acids, small molecules, and peptides [5]. - The article emphasizes the diversification of antibody drugs, with new generations such as bispecific antibodies and antibody-drug conjugates (ADCs) gaining traction. Chinese biotech companies are increasingly participating in global markets through collaborations, mergers, and acquisitions [5]. Event Details - The 2025 AntibodyPlus Innovation Summit will take place on June 25-26, 2025, in Suzhou, China, bringing together top scientists, clinicians, multinational pharmaceutical companies, local biotech firms, and investors to discuss opportunities and challenges in the AntibodyPlus era [5]. Agenda Highlights - The summit will feature various sessions focusing on clinical needs, drug development, and international cooperation, including discussions on significant advancements in lung cancer treatments and the development of innovative antibodies for women's health and hair loss [10][11]. - Panels will address global pharmaceutical innovation trends, investment hotspots, and challenges faced in the development of new antibody therapies [11][15]. Concurrent Forums - The summit will include multiple forums, such as discussions on the next innovations in multi-antibody drugs and the development of conjugated drugs, with expert speakers sharing insights on clinical progress and market opportunities [13][21]. Networking Opportunities - The event will provide networking opportunities for attendees, including a private board meeting focused on global strategies for drug development and market entry [54].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights that the turning point for research services has arrived, with a focus on companies such as Haoyuan Pharmaceutical, Bidai Pharmaceutical, and Baiaosaitu [1] - The A-share pharmaceutical index has seen a decline of 6.3% this week and an increase of 4.6% year-to-date, underperforming the CSI 300 by 3.9% and outperforming it by 2.3% respectively [4][9] - The report emphasizes the positive impact of recent policies accelerating the development of innovative drugs, which benefits upstream companies involved in research and production [4][18] Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 6.3% this week and increased by 4.6% year-to-date, while the H-share biotechnology index has dropped by 8.2% this week but increased by 48% year-to-date [4][9] - The report notes that the pharmaceutical sector has experienced significant declines, particularly in innovative drugs, with H-shares showing more pronounced drops due to previous high gains [4][9] Research and Development Progress - Recent policies have accelerated the approval processes for innovative drugs, with the FDA reducing NDA approval times from 10-12 months to 1-2 months, and China's CDE shortening IND review times from 60 days to 30 days [18][19] - The report indicates that the demand from the industrial sector is recovering, which will benefit early-stage research suppliers [20] Market Insights - The report suggests focusing on companies that are expected to benefit from the early-stage research demand, mergers and acquisitions, and the commercialization of innovative drugs [19] - Specific companies to watch include Haoyuan Pharmaceutical, Bidai Pharmaceutical, Baiaosaitu, and others in the life sciences service sector [4][19] Investment Strategy - The report recommends a ranking of sub-sectors for investment: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [11] - It highlights specific companies for investment based on growth potential, low valuations, and high dividend yields, particularly in the traditional Chinese medicine sector [11][13]